[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07292376":3,"trial-entities:NCT07292376":70,"trial-summary:NCT07292376":74},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":20,"study_type":21,"primary_purpose":13,"phases":22,"enrollment_info":24,"interventions":27,"primary_outcomes":32,"secondary_outcomes":37,"sex":41,"minimum_age":42,"maximum_age":16,"healthy_volunteers":14,"eligibility_criteria":43,"std_ages":50,"locations":53,"central_contacts":63,"overall_officials":64,"references":68,"see_also_links":69},"NCT07292376","FP00005110","Implementing VTE Prevention in Ambulatory Cancer Care","ENROLLING_BY_INVITATION","2026-07-30","2025-12","2025-12-18","2025-10-01","University of Vermont","OTHER",false,"assess effectiveness of a , compared with usual care, to assess\n\nThe goal of this study is to learn if a modified clinical program can improve adherence to guideline recommendations for prevention of venous thromboembolism in ambulatory patients with cancer. The main question\\[s\\] it aims to answer are:\n\nDoes the modified program improve number of ambulatory oncology patients starting systemic treatment getting VTE risk-assessment? Does the modified program improve the number of patients receiving appropriate preventative anticoagulation? Researchers will compare to usual care (no clinical program).\n\nParticipant clinicians will be asked to\n\n* receive education about VTE prevention recommendations\n* carry out risk assessment, anticoagulation discussions, and document the results Participant patients will receive care from clinicians participating in the study as part of their cancer care.",null,[18,19],"Venous Thromboembolism","Neoplasms",[],"INTERVENTIONAL",[23],"NA",{"count":25,"type":26},25,"ESTIMATED",[28],{"type":13,"name":29,"description":30,"armGroupLabels":31},"Clinical program","Revised Vermont Model clinical program, including standardized education and training for oncology care team, clinical decision support and revised workflow for VTE risk assessment and thromboprophylaxis.",[29],[33],{"measure":34,"description":35,"timeFrame":36},"Documented VTE risk assessment","Proportion of new patients who have documented VTE risk assessment","30 days after new patient appointment",[38],{"measure":39,"description":40,"timeFrame":36},"Appropriate thromboprophylaxis","Proportion of identified high-risk patients with prescription for thromboprophylaxis and low-risk patients without thromboprophylaxis","ALL","18 Years",{"inclusion":44,"exclusion":47,"raw_text":49},[45,46],"Clinicians: practicing oncologist at study clinic site (UVMMC)","Patients: diagnosis of cancer; starting new systemic cancer-directed therapy at a study clinic site under the direction of the enrolled clinician",[48],"none","Inclusion Criteria:\n\n* Clinicians: practicing oncologist at study clinic site (UVMMC)\n* Patients: diagnosis of cancer; starting new systemic cancer-directed therapy at a study clinic site under the direction of the enrolled clinician\n\nExclusion Criteria:\n\n* none",[51,52],"ADULT","OLDER_ADULT",[54],{"facility":55,"city":56,"state":57,"zip":58,"country":59,"geoPoint":60},"Vermont Health","Burlington","Vermont","05405","United States",{"lat":61,"lon":62},44.47588,-73.21207,[],[65],{"name":66,"affiliation":12,"role":67},"Karlyn Martin, MD","PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":71,"biomarkers":73},[72],"Neoplasm",[],{"nct_id":4,"found":14,"summary":16,"prompt_version":16}]